Global POC HbA1C Testing Market Strategic Research Report

Scope of the Report

The global POC HbA1C Testing market size is predicted to grow from US$ 610 million in 2025 to US$ 1,080 million in 2032; it is expected to grow at a CAGR of 8.6% from 2026 to 2032.

HbA1c levels, which reflect the average plasma glucose concentration over the preceding three months, play a pivotal role in the diagnosis, assessment, and monitoring of diabetes. HbA1c is your average blood glucose (sugar) levels for the last two to three months. The immediate feedback of HbA1c levels is highly effective for controlling plasma glucose levels and point-of-care (POC) instruments, characterized as fast, portable, and easy-to-use, have been shown to be suitable for providing rapid feedback of HbA1c levels. In this report, we mainly study the devices for POC HbA1C Testing without services.

Market Drivers:

The growing prevalence of diabetes worldwide is a key driver for the POC HbA1c testing market. As the number of diabetic and prediabetic patients continues to rise, there is an increasing need for quick and efficient monitoring solutions to manage blood sugar levels effectively. POC HbA1c testing provides immediate results, allowing for real-time clinical decision-making and reducing patient dependence on centralized laboratories. Additionally, advancements in technology have led to the development of highly accurate, portable, and user-friendly devices, expanding their adoption in hospitals, clinics, and even home settings. Government initiatives promoting early diabetes detection and personalized treatment plans further boost market growth.

Market Challenges:

Despite its advantages, POC HbA1c testing faces several challenges, including high costs and reimbursement limitations in some healthcare systems, which may hinder widespread adoption. Additionally, variations in accuracy and standardization among different POC devices pose concerns regarding result reliability, especially when compared to laboratory-based testing. Regulatory approvals and compliance with stringent quality standards also create barriers for manufacturers entering new markets. Furthermore, lack of awareness and limited access to POC testing in certain developing regions restricts its potential reach, requiring further investments in education and healthcare infrastructure.

This report presents a comprehensive overview of the global POC HbA1C Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Immunoassay
• Boronate Affinity
• Others

Segment by players, this report covers

• Abbott
• Siemens Healthineers
• Roche
• Bio-Rad
• GREEN CROSS MEDIS
• Trinity Biotech
• HUMAN Diagnostics
• Sinocare (PTS Diagnostics)
• Erba Diagnostics
• EKF Diagnostics
• OSANG Healthcare
• SD Biosensor
• Aidian
• Boditech Med
• i-SENS

Segment by Application

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global POC HbA1C Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital and Clinics, Diagnostic Laboratories, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact